Methodological considerations in the interpretation of ASCENT-03

Area of Science:

• Oncology
• Medical Science

Background:

• Metastatic triple-negative breast cancer (mTNBC) often presents unmet needs, particularly in patients ineligible for PD-(L)1 inhibitors.
• PD-L1 expression levels (CPS < 10) characterize a significant subset of mTNBC patients who may not receive subsequent therapies.

Purpose of the Study:

• To evaluate the efficacy of sacituzumab govitecan (SG) versus chemotherapy as a first-line treatment for patients with previously untreated metastatic triple-negative breast cancer (mTNBC).
• To address the unmet need in mTNBC patients ineligible for PD-(L)1 inhibitors.

Main Methods:

• The ASCENT-03 trial compared sacituzumab govitecan (SG) with chemotherapy in a first-line setting.
• Progression-free survival (PFS) was a primary endpoint.

Main Results:

• Sacituzumab govitecan (SG) demonstrated a statistically significant improvement in progression-free survival (PFS) compared to chemotherapy.
• This benefit was observed in the specific population of previously untreated mTNBC patients ineligible for PD-(L)1 inhibitors.

Conclusions:

• Sacituzumab govitecan (SG) shows promise as a first-line treatment option for a specific mTNBC population.
• Mature overall survival data, adjusted for crossover, are necessary to solidify SG's position as a standard of care in this setting.